[Effectiveness of ceftibuten++ in the sequential therapy of respiratory and urinary tract infections].

Abstract

A prospective, comparative, multicentre trial was performed to study the efficacy and safety of ceftibuten in respiratory and complicated urinary tract infections. Patients (n = 152) requiring parenteral 2nd or 3rd generation cephalosporine therapy were randomly assigned to continue parenteral therapy (Group A) or to receive oral ceftibuten 400 mg, or 9 mg/kgbw/day (Group B) from the 3.-5. days on. The patients, whose conditions have not improved significantly at day 3-5, were omitted from the study, so the number of evaluated patients was 131. In Group A, out of 59 patients 51 were clinically cured, the bacteriological eradication rate was 47/54. In Group B, out of 72 patients 67 were cured and 62 out of 66 pathogens were eradicated. The cost of step-down therapy was 44.3% less than the parenteral one. No adverse effect was observed that could surely be attributed to ceftibuten. According to these data, ceftibuten can be used in step-down therapy in respiratory and urinary tract infections requiring parenteral therapy at first and that offers a safe and less expensive therapeutic approach.

• Authors: E Székely, E Ludwig
• Journal: Orvosi hetilap (Orv Hetil) Vol. 140 Issue 30 Pg. 1681-5 (Jul 25 1999) ISSN: 0030-6002 [Print] Hungary
• Vernacular Title: A ceftibuten hatékonysága légúti és húgyúti infekciók szekvenciális terápiájában. Multicentrikus Vizsgálati Csoport Résztvevöi.
• PMID: 10461448 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Cephalosporins
• Ceftibuten

Topics

• Ceftibuten
• Cephalosporins (pharmacology, therapeutic use)
• Humans
• Respiratory Tract Infections (drug therapy)
• Urinary Tract Infections (drug therapy)